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Abstract
Introduction: The opioid epidemic has become an immense problem in North America, and despite decades of
research on the most effective means to treat opioid use disorder (OUD), overdose deaths are at an all-time high,
and relapse remains pervasive.
Discussion: Although there are a number of FDA-approved opioid replacement therapies and maintenance
medications to help ease the severity of opioid withdrawal symptoms and aid in relapse prevention, these medications are not risk free nor are they successful for all patients. Furthermore, there are legal and logistical bottlenecks to obtaining traditional opioid replacement therapies such as methadone or buprenorphine, and the
demand for these services far outweighs the supply and access. To ﬁll the gap between efﬁcacious OUD treatments and the widespread prevalence of misuse, relapse, and overdose, the development of novel, alternative, or
adjunct OUD treatment therapies is highly warranted. In this article, we review emerging evidence that suggests
that cannabis may play a role in ameliorating the impact of OUD. Herein, we highlight knowledge gaps and discuss cannabis’ potential to prevent opioid misuse (as an analgesic alternative), alleviate opioid withdrawal symptoms, and decrease the likelihood of relapse.
Conclusion: The compelling nature of these data and the relative safety proﬁle of cannabis warrant further exploration of cannabis as an adjunct or alternative treatment for OUD.
Keywords: cannabis; opioid addiction; opioid treatment; relapse prevention

Introduction
The opioid epidemic has become an increasingly pressing problem with an estimated 26–36 million people
abusing opioids around the world.1 At the time of this
publication, the Centers for Disease Control reports
that 115 people die every day of an opioid related
cause in the United States, and more than 33,000 people
lost their lives to an accidental opioid overdose in the
United States in 2015 alone.1–4 The United States consumes 80% of the world’s supply of prescription opioid
analgesics (POAs), and opioid prescriptions have
climbed by 300% since 1991.5 The rise in opioid prescriptions has also widened the demographic of individ-

uals dying from opioid overdose; historically, overdose
was most prevalent in urban, minority adolescent
males; however, today these lethal effects are similar
across race, gender, socioeconomic status, and geography.7–11 The spike in prescriptions has also directly contributed to an increase in the number of ﬁrst-time
consumers of illicit opioids (heroin, which is commonly
laced with fentanyl or its analogs), which has continued
to climb since the mid 1990’s.6 Patients who become
physically dependent upon POAs frequently switch to illicit opioids because POAs are more costly and/or difﬁcult to obtain.3,8,12,13 However, ease of access is a
dangerous tradeoff for the lethal risk that is associated
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with synthetic opioids. Fentanyl, for instance, is 100
times more potent than morphine, which partially explains why there was a 250% increase in synthetic opioid
mortality between 2012 and 2015.14,15
This unprecedented public health crisis warrants the
investigation of novel sustainable interventions which
would directly address the current opioid misuse crisis,
complement current treatment strategies, and prevent
future misuse through alternative ﬁrst line analgesics.
Mechanistic Interactions between
Cannabis and Opioids
The endocannabinoid and opioidergic systems are known
to interact in many different ways, from the distribution
of their receptors to cross-sensitization of their behavioral pharmacology. Cannabinoid-1 (CB1) receptors
and mu opioid receptors (MORs) are distributed in
many of the same areas in the brain, including but not
limited to the periaqueductal gray,16,17 locus coeruleus,18,19 ventral tegmental area (VTA), nucleus accumbens, prefrontal cortex (PFC),20 central amygdala (CeA),
bed nucleus of stria terminalis (BNST),21 caudate putamen (CP), substantia nigra, dorsal hippocampus, raphe
nuclei, and medial basal hypothalamus.22 The extent of
this overlapping expression and frequent colocalization
of the CB1 and MOR provide clear morphological underpinnings for interactions between the opioid and
cannabinoid systems in reward and withdrawal.19,23
There is a bidirectional relationship between MORs
and CB1 receptors in the rewarding properties of drugs
of misuse.20,24–28 That is, modulation of the CB1 receptor has profound effects on the rewarding properties of
opioids, and vice versa. For example, MOR and CB1 receptors are reciprocally involved in the development of
drug-induced conditioned place preference (CPP).
Coadministration of a cannabinoid antagonist and
morphine attenuates the development of morphine
CPP,26 and coadministration of an opioid antagonist
blocks tetrahydrocannabinol (THC)-induced CPP.25
Interestingly, microinjections of CB1 agonists into the
medial PFC creates an aversion to doses of morphine
that are normally rewarding (CPP), while CB1 antagonism in this brain region creates a rewarding effect of
subthreshold morphine doses.24 In addition, administration of cannabinoids to MOR knockout (KO) mice
produces a weaker CPP compared to wild-type animals,22 reviewed in Wills and Parker.27 This mutual involvement in reward is at least partially mediated by
presynaptic cannabinoid and opioid disinhibition of
dopamine neurons in the VTA, a well-characterized
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mechanism in the rewarding properties of drugs of
misuse.20 Although these mechanisms have not been
well studied in humans, one study has found CB1 upregulation in the reward pathway of individuals who use
opioids, which supports a role for the endocannabinoid
system in the development of opioid misuse.29
There is abundant support for the role of CB1 receptors
in the rewarding effects of opioids and the amelioration of
tolerance. However, the effects of endogenous and exogenous cannabinoids in opioid withdrawal are somewhat
paradoxical: endogenous cannabinoids seem to have no
role in somatic withdrawal,27,30–32 yet exogenous CB1 agonists readily alleviate somatic symptoms such as escape
jumps, diarrhea, weight loss, and paw tremors.28,33,34
Endogenous cannabinoid tone within the amygdala is
also involved in the affective component of opioid withdrawal, as blockade of CB1 receptors in the CeA or BNST
ameliorates opioid withdrawal.21 The kappa opioid receptor (KOR) system may also play a role in cannabis’
impact on the affective opioid withdrawal, given its pivotal contributions to dysphoria and negative effect.35
However, both KOR agonism (with U50, 488H30) and
KOR antagonism (naloxone31,32) have both been shown
to attenuate conditioned place aversion in CB1 KO
mice.30 These contradicting data highlight the need for
additional mechanistic insights into the involvement of
the CB1 receptor in opioid reward and withdrawal.
Cannabis as a First Line Analgesic
The primary use for both prescription opioids and cannabis is for analgesia. Currently, up to 90% of patients in
state-level medical cannabis registries list chronic pain
as their qualifying condition for the medical program.36
In an exhaustive review, the National Academies of Science and Medicine recently conﬁrmed the efﬁcacy of
cannabis for chronic pain in adults.36 Interestingly,
when given access to cannabis, individuals currently
using opioids for chronic pain decrease their use of opioids by 40–60% and report that they prefer cannabis
to opioids.37–42 Patients in these studies reported
fewer side effects with cannabis than with their opioid
medications (including a paradoxical improvement in
cognitive function) and a better quality of life with cannabis use, compared to opioids. Despite the vast array
of cannabis products and administration routes used
by patients in states with medical cannabis laws, cannabis has been consistently shown to reduce the opioid
dose needed to achieve desirable pain relief.41,43
One of the mechanisms that may explain the opioid
sparing effects of cannabis is its ability to produce
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synergistic analgesia.44–46 In humans, subanalgesic doses
of THC and morphine are equally unsuccessful at reducing the sensory or affective components of pain; however,
when the same doses of THC and morphine are coadministered, they produce a signiﬁcant reduction in the affective component of pain.47 These synergistic effects
are also observed when patients using opioids for pain
vaporize whole-plant cannabis, as opposed to experimentally administered isolated THC.48 Adjunct whole
plant cannabis has no effect on the pharmacokinetics
of opioids, which further supports a synergistic mechanism behind the opioid sparing and enhanced analgesia
produced by cannabis.48 Furthermore, in pre-clinical
models, coadministration of opioids and cannabinoids
attenuates the development of opioid tolerance.49,50
Combined, these clinical and pre-clinical data suggest that analgesic synergy produced by coadministered
cannabis and opioids could be harnessed to achieve
clinically relevant pain relief at doses that would normally be subanalgesic. This strategy could have significant impacts on the opioid epidemic, given that it
could entirely prevent two of the hallmarks of opioid
misuse: dose escalation and physical dependence.
Because patients report substituting cannabis for
several types of pharmaceutical drugs, including opioids, benzodiazepines, and antidepressants,51 analgesic
synergy may not entirely explain the opioid-sparing effects of cannabis in pain patients. Economic and lifestyle considerations may also play a pivotal role in
opioid sparing and substitution. Patients report that
their reasons for substituting cannabis for other medications include less severe side effects, less withdrawal
potential, ease of access, and better symptom management for their conditions.52
Although there is insufﬁcient clinical literature to support the use of cannabis as a treatment for acute pain,
there is a long-standing body of pre-clinical evidence
that demonstrates the antinociceptive effects of cannabinoids in pain-free, drug-naive animals.17,49,53–57 The
mechanisms of cannabinoid antinociception are remarkably similar to those of opioid analgesics. Both
the CB1 and MOR are G-protein coupled receptors,
and agonist-initiated disinhibition of GABA release in
the descending pain pathway is just one example of
overlapping antinociceptive mechanisms between these
drugs.17,23,58–62 Evidence supporting the role of cannabis
in acute, nonsevere pain management could lead to a
substantial reduction in opioid prescription rates,
thereby eliminating patient exposure to the risks of opioid dose escalation and physical dependence. This criti-
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cal gap in the clinical literature and potential clinical
impacts of this therapy warrants further exploration of
the efﬁcacy of cannabis for acute pain relief.
Current Opioid Use Disorder Therapies
and Their Shortcomings
The most prominent and pervasive problem in opioid
use disorder (OUD) treatment is the prevention of
drug relapse, which is extremely common during
acute withdrawal (detoxiﬁcation), as well as during
protracted recovery after physical withdrawal symptoms have subsided.63–66 Abstinence-based protocols
are particularly ineffective, as 85% of individuals relapse within 12 months of the initiation of treatment.65
In-patient residential treatment facilities do not appear
to improve abstinence-based therapy, as relapse rates in
this paradigm are as high as 80%, when measured 2
years after treatment initiation.67 Compared to abstinence, opioid replacement and medication-assisted
therapies, which began in the 1960s, are more efﬁcacious for relapse prevention; however, there are currently only four FDA-approved medications for the
treatment of OUD.68–71 Off-label prescription medications such as benzodiazepines and antiemetics are also
common, but these therapies are largely directed at
symptom management during acute detoxiﬁcation
rather than relapse prevention.72 In this review, we
focus on the most widely used OUD therapies, their
shortcomings, and the bottlenecks to accessing them.11
Methadone, a full MOR agonist, was approved by the
FDA in 1974 to aid in opioid cessation.9,73 Individuals
enrolled in consistent dose methadone maintenance
programs are more likely to stop using nonprescribed
opioids than individuals not enrolled in the maintenance program.74 Although methadone has an encouraging safety proﬁle,75 it carries some risk for misuse
and mortality when the dose exceeds the patient’s
level of tolerance.76,77 Withdrawal symptoms from
methadone mimic those of other opioids when stopped
abruptly or tapered too quickly, and these symptoms
last up to 3 weeks longer than withdrawal from other
opioids.9,78,79 There are only 1590 methadone distributers in the United States, which are highly regulated
clinics that are concentrated in urban areas, creating
geographical disparities in OUD treatment.10,11,79 In
addition to geographical barriers, these clinics frequently have stringent and stigmatizing compliance
requirements, such as daily visits and frequent urine
screenings for illicit drugs.11,80 Although these barriers to treatment could potentially be addressed
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through concerted efforts to expand access, 40% of
patients still relapse within 1 year of initiating methadone therapy.67
Buprenorphine (Subutex) is a partial MOR agonist and
KOR antagonist that can reduce withdrawal symptoms,
cravings, and additional opioid use.76,81,82 The inclusion
of naloxone in some buprenorphine formulations (Suboxone, Zubsolv) is intended to reduce misuse by precipitating withdrawal when it is used intravenously,82,83 and
despite the presence of naloxone, there is still some risk
for misuse and overdose.77,83,84 The inclusion of naloxone can also induce withdrawal when administered too
soon after the most recent dose of other opioids.63,67,85
Unlike methadone, Suboxone offers a primary care
approach to medication-assisted therapy, as it can be dispensed by a pharmacy rather than a specialized clinic.86,87
However, only 3% of physicians possess the additional
Drug Enforcement Agency credentials required to prescribe buprenorphine,76,88 and there are strict limits on
the number of patients they are permitted to serve.89
Buprenorphine-licensed physicians also tend to be concentrated in larger cities, leaving 46.8% of counties in
the United States, especially rural areas and the Midwest,
with a shortage in convenient access to these treatment
options.88,90,91 While long-term treatment retention
with buprenorphine or Suboxone is not as well characterized as methadone, a Swedish study has shown retention
rates of up to 75% following a year of buprenorphine/
Suboxone treatment.92 However, a 24-week clinical trial
in the United States reveals that buprenorphine retention
is only 46%.93
Evidence suggests that the most effective tool for relapse prevention is medication-assisted pharmacotherapy, combined with social support.76,78,94,95 Because of
the overwhelming evidence that supports this concurrent treatment model, there is little rationale to deviate
from this approach. However, expanded access to these
therapies is highly warranted, as are novel and alternative therapies which improve efﬁcacy, diminish geographical disparities, and eliminate the need for
specialty physicians.96
Cannabis During Acute Opioid Withdrawal
The ﬁrst barrier to overcoming OUD is getting patients
through the acute withdrawal period, or detoxiﬁcation.
Although pharmacotherapies such as methadone and
buprenorphine are largely successful and widely utilized
for this purpose, there are shortcomings to this approach,
which are highlighted above.9,76,78,80,82,83,87,89–91,97 In
May of 2018, the FDA approved the use of lofexidine,
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an alpha-2 adrenergic receptor agonist for acute
(14 day) opioid withdrawal. Lofexidine provides substantially more symptom relief than placebo; however,
the comparative efﬁcacy of lofexidine in combination
with long-acting opioid agonists or opioid antagonists
is still being characterized.71,98–100
There is also nascent evidence that suggests that cannabis may be an efﬁcacious tool during the acute opioid
withdrawal period. Numerous pre-clinical studies have
shown that cannabis and cannabinoids decrease opioid
withdrawal symptoms.6,33,34,97,101–103 Although this evidence supports the use of cannabinoids as a possible
treatment in OUD treatment,28 conﬂicting evidence
demonstrates that CB1 agonism increases the rewarding
properties of opioids22,102 and may actually increase the
severity of opioid withdrawal symptoms.18,104 These
conﬂicting data highlight the need for a mechanistic
characterization of CB1 agonism as a therapeutic target
for opioid withdrawal, a need that is further substantiated by the pharmacology of CB1 antagonism. For instance, some studies show that acute administration of
SR-141716A, a CB1 antagonist, can reduce opioid withdrawal; however, this effect is profoundly affected by the
experimental conditions.22,105 Because this effect can be
recapitulated in CB1 KO mice, CB1 antagonism only
partially mediates these effects.102 To complicate the
story further, the administration of cannabidiol (CBD),
a very promiscuous phytocannabinoid with at least a
dozen mechanisms of action, also alleviates naloxoneprecipitated withdrawal in morphine tolerant rats.106–112
Although the mechanisms by which cannabinoids alleviate opioid withdrawal are complex and unclear, some
reports suggest that cannabis may alleviate opioid withdrawal in humans.18,113 For instance, patients engaging
in medication-assisted detoxiﬁcation from opioids
reported using cannabis when opioid maintenance
doses were not high enough to prevent withdrawal
and cravings.114 However, some individuals reported
that cannabis was often ineffective and sometimes worsened overall severity of the withdrawal symptoms.
Because the phytochemical makeup and cannabinoid
content of cannabis have a signiﬁcant effect on subjective
human experiences,115 it is plausible that these variable
experiences are the result of variable phytochemistry
in cannabis products that are self-selected by study participants. Unfortunately, blinded, placebo-controlled
clinical trials evaluating the efﬁcacy of cannabis, either
alone or as an adjunct therapy for acute opioid withdrawal, are lacking. This is not entirely surprising,
given cannabis’ status as a Schedule I substance in the

Wiese and Wilson-Poe; Cannabis and Cannabinoid Research 2018, 3.1
http://online.liebertpub.com/doi/10.1089/can.2018.0022

United States, which precludes federal funding to investigate cannabis as a medication-assisted therapy.
Unlike whole-plant cannabis, dronabinol, an FDAapproved analog of THC, has been evaluated for opioid
withdrawal relief in a placebo-controlled study in patients receiving the opioid antagonist naltrexone. Lowdose adjunct dronabinol improved the tolerability of
symptoms such as insomnia, reduced appetite, and reduced energy levels during opioid detoxiﬁcation, whereas
adverse events such as tachycardia were reported
at higher dronabinol doses.113,116,117 In many studies,
cannabinoids were safe and tolerable when coadministered with an opioid or opioid replacement medication.47,113,118–120 However, the comparative efﬁcacy of
dronabinol or other cannabinoids versus traditional replacement therapies such as methadone or buprenorphine remains to be elucidated. Given the efﬁcacy and
tolerability of Sativex (a whole-plant cannabis derivative) for pain and spasticity, investigation of adjunct Sativex for opioid withdrawal is warranted.121–123
Like opioids, chronic cannabis exposure induces the
development of tolerance, physical dependence, and
withdrawal symptoms during abstinence. Patients
commonly report that cannabis withdrawal symptoms,
most commonly anger, aggression, irritability, anxiety,
decreased appetite, weight loss, restlessness, and sleeping difﬁculties,124–129 are similar to those produced by
nicotine withdrawal.129 Comparatively, the magnitude
and severity of cannabis withdrawal are signiﬁcantly
and substantially more benign than opioid withdrawal.20,126 In addition, and unlike opioids, cannabinoid
withdrawal and subsequent relapse are nonlethal after
periods of abstinence. The reduced intensity of cannabinoid withdrawal symptoms compared to opioids
could at least partially be explained by the prolonged
period of metabolization of cannabinoids in the
body,102 contributing to the mounting support for cannabis as a harm-reduction tool to combat OUD.
Cannabis as a Harm Reduction Tool in OUD
Pre-clinical evidence suggests that the CB1 receptor
plays a critical role in opioid reward. Cannabinoid antagonism reduces the rewarding properties of opioids
and prevents reinstatement of drug seeking.105,130,131
However, these effects were not reproducible in
human clinical trials.132–134 Unlike CB1 antagonism,
CB1 agonism may play a role in OUD treatment. Several
studies have shown that adjunct cannabis decreases
opioid consumption or prevents opioid dose escalation.37–42,121,135 Although these ﬁndings are promising,
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several other studies have shown that cannabis use either has no impact on opioid consumption or may increase nonmedical opioid use.136–138
The mechanisms underlying cannabis alteration of opioid consumption are yet to be determined; however, there is
signiﬁcant pre-clinical evidence which suggests that CBD,
one of the most prevalent cannabinoid molecules in cannabis, plays a critical role. CBD does not have reinforcing effects in rodents, which supports its low potential for
misuse.16,139 CBD has been shown to reduce the rewarding
aspects of multiple drugs of abuse, such as cocaine, amphetamine,16 and nicotine.140 Administration of CBD
also attenuates morphine CPP and cue-induced reinstatement of heroin self-administration in rats, without creating
any aversive or rewarding effects on its own.106,141–143
These ﬁndings provide promising rationale for the
use of CBD in opioid relapse prevention in humans.
In fact, pilot clinical studies have shown that in individuals recently abstinent from heroin, CBD reduces heroin craving.142 This effect occurs as soon as 1 h after
administration and lasts for up to 7 days. Adjunct
CBD appears to be safe and tolerable, as 400 and
800 mg oral CBD administration does not intensify
the effects of intravenous fentanyl or create any adverse
effects.118 Because CBD is neither intoxicating nor rewarding and has an extremely large therapeutic window and impressive safety proﬁle, the use of CBD to
inhibit opioid craving has great therapeutic potential.
Adjunct cannabis use alongside current treatment
strategies could help to improve the number of individuals engaging in OUD treatment, as well as increase treatment retention rates. Both dronabinol and intermittent
whole-plant cannabis appear to increase the length of
time patients remain in treatment for OUD.6,113 However, chronic cannabis consumption during naltrexone
treatment was ineffective at improving treatment retention, highlighting the need for further research into the
dose and frequency of cannabis use in OUD treatment
retention and relapse prevention.144 Although the ubiquitous and ever-growing regulated cannabis markets
across North America could potentially address the
aforementioned shortcomings in OUD treatment accessibility and retention, there are currently very few addiction and recovery centers that have embraced concurrent
social support and cannabis-assisted OUD treatment.51
This is unsurprising given the lack of empirical evidence
to support this approach, and the lack of federal research
funding that would support this work.
In addition to the clinical and experimental observations outlined above, epidemiological investigations in
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U.S. states with legal cannabis have provided insight into
the promising role for cannabis in the opioid crisis. The
implementation of both medical and adult-use cannabis
laws appears to have a signiﬁcant impact on opioid consumption and overdose. These states experience a 23%
reduction in nonfatal opioid overdoses, as measured at
hospital emergency departments.145 By analyzing
death certiﬁcates, Bachhuber et al. found a 24% reduction in the annual rate of fatal opioid overdoses in the
ﬁrst year following medical cannabis legalization,146 an
effect that gets larger the longer a state has had legal cannabis (33% in California, which has had medical use
since 1996 and the lowest rate of opioid overdose fatalities in the country).146,147 This ﬁnding was also seen in
data from the FARS, which demonstrates a similar drop
in mortalities of opioid positive automobile accidents
in states with implemented cannabis legalization for individuals aged 21–40.148 The mechanisms underlying
cannabis’ ability to reduce opioid hospitalization and
mortality are unclear; however, analysis of the Medicare
Part D prescription drug program has unveiled the possibility that cannabis may be serving as an analgesic alternative to opioids for individuals living in these
states.149 The number of ﬁlled POAs is substantially
lower in states with the most liberal cannabis laws,
where there are 3.742 million fewer daily doses than in
states with the most prohibitive laws.150
These epidemiological impacts are not exclusive to
opioid prescriptions, hospitalizations, and mortality;
the U.S. economy could also beneﬁt from expanded cannabis legalization. Opioids cost patients and insurance
companies upwards of 2.6 billion dollars in healthcare
costs annually.151 While cannabis is still federally illegal,
and in most cases dispensary purchases are not eligible
to be covered under any healthcare insurance plan,
states with legalized cannabis have seen signiﬁcant decreases in Medicare Part D prescription drug spending,
including, but not limited to, prescription opioids.149,152–155 Reductions in spending from Medicare
Part D were over $165 million dollars.149 If cannabis
were removed from Schedule I of the Controlled Substance Act and more patients had access to cannabis,
savings from pharmaceutical costs incurred by the
Medicare Part D prescription plan are projected to continue to climb.149
Shortcomings of Cannabis
in Medication-Assisted Therapy
Although the literature thoroughly supports the safety
and tolerability of cannabis,38,118,142,156 there is con-
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ﬂicting evidence for its efﬁcacy as a treatment for opioid misuse. Throughout the history of methadone
administration, patients have reported that cannabis
provides relief from opioid withdrawal symptoms, as
well as breakthrough pain and anxiety.119 However,
other evidence demonstrates that cannabis does not
relieve withdrawal symptoms for individuals undergoing methadone tapering, and some participants
even reported increased severity of their withdrawal
symptoms.104 All the participants in the latter study
procured their own cannabis and reported smoking
as the route of administration. Because the dose of
cannabinoids and phytochemical makeup of wholeplant cannabis have signiﬁcant impacts on physiological responses (such as tachycardia) and subjective
experiences (such as anxiety), additional research is
needed to characterize maximally efﬁcacious treatment protocols.116,157 When used to treat opioid withdrawal symptoms, undesirable side effects also occur
in a dose-dependent manner for the FDA-approved
cannabinoid dronabinol.113 The homogenous and
consistent formulation of this pharmaceutical combined with the logistical ease of prescribing the drug
may make it more feasible than whole-plant cannabis
for clinical trials on cannabinoid alleviation of opioid
withdrawal symptoms and relapse prevention.
Despite the promising results of reducing or maintaining a consistent opioid dose, it is plausible that the
substitution of one rewarding substance (opioids) for
another (THC) could be problematic, leading to cannabis use disorder (CUD). In 2016, *1.4–2.9% of adults
over the age of 18 in the United States met criteria for
CUD.79 With revisions to the criteria of substance
use disorders in 2013, *19% of individuals who use
cannabis throughout their lifetime would eventually
meet the Diagnostic and Statistical Manual of Mental
Disorders, Fifth Edition (DSM-5) criteria for CUD.153
The interpersonal or employment hardships experienced by these individuals that resulted in the meeting
of DSM criteria may have simply been due to the legality of cannabis use; that is, a false CUD diagnosis is less
likely to occur in the postprohibition era, when patients
are no longer breaking the law.
Risks of CUD seem to be correlated with higher THC
concentrations,153 which is a valid concern in legal markets where average THC potency is upward of 20%.158
Recreational users of cannabis have historically consumed cultivars higher in THC and lower in CBD,
due to the desired intoxicating effects of THC.38 Medical users, however, have turned to cultivars higher in
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CBD and lower in THC in an attempt to optimize the
medicinal beneﬁts of cannabis.38,153 Although misuse
potential is a valid concern, it is notable that the misuse
liability of cannabis is very low.159 One possible approach to alleviate the concern of misuse is the concurrent administration of opioid antagonists. This
approach seems to reduce the rewarding properties,
but not the hyperphagia or withdrawal-relieving properties of THC.160–164 These data suggest that combined
cannabis and opioid-antagonist therapy could be an effective tool against OUD, while also minimizing the
risk for CUD. Because cannabis does not carry the
risk of fatal overdose, the use of cannabis as a harmreduction treatment in the opioid epidemic warrants
further investigation.
Summary and Future Directions
The opioid overdose epidemic is arguably the worst
public health crisis in U.S. history. At the time of this
publication, more people are dying than at the peak
of the AIDS epidemic, and for the ﬁrst time, drug overdoses outnumber automobile and handgun deaths.165
A continental crisis of this magnitude warrants the immediate implementation of novel strategies that prevent opioid misuse, overdose, and death.
Growing pre-clinical and clinical evidence appears to
support the use of cannabis for these purposes. The evidence summarized in this article demonstrates the potential cannabis has to ease opioid withdrawal symptoms,
reduce opioid consumption, ameliorate opioid cravings,
prevent opioid relapse, improve OUD treatment retention, and reduce overdose deaths. Cannabis’ greatest potential to positively impact the opioid epidemic may be
due to its promising role as a ﬁrst line analgesic in lieu
of or in addition to opioids. The comparative efﬁcacy
of cannabis alone or in conjunction with current
medication-assisted OUD therapies is not well characterized. However, no other intervention, policy, pharmacotherapy, or treatment paradigm has been as impactful as
cannabis legislation has been on the rates of opioid consumption, overdose, and death.
Many of the barriers that prevent people from
accessing traditional OUD treatment do not apply to
cannabis therapy, and access to cannabis medicine is
rapidly growing as more U.S. states roll back prohibition. However, a major barrier in universal patient
access and improvement in the opioid epidemic is cannabis’ status as a Schedule I controlled substance.166
Undoubtedly, more high-quality clinical evidence is
needed to further support the use of cannabis to combat

185

OUD; however, federal grant funding that would support these types of clinical trials is currently outside
the scope of interest of the National Institutes of Health
(because of Schedule I, cannabis is federally considered
to have no medical beneﬁt). Patients, healthcare providers, and regulating bodies would all greatly beneﬁt from
additional evidence that ﬁlls in massive gaps in the
knowledge base about the utility of cannabis for OUD
treatment: dosing, cannabinoid content and ratios, bioavailability, contraindications, misuse liability, route of
administration, and many other questions remain. Even
the clinical work that has been conducted thus far may
have little validity in the modern landscape of legalized
cannabis; all federally-funded cannabis research in the
United States is conducted using a single source of cannabis (NIDA drug supply), which is notoriously low in
potency and quality, and does not resemble the staggering phytochemical variability in whole-plant cannabis
products in regulated state markets.36 These barriers
to research funding and access to ‘‘real world’’ cannabis
for clinical research directly contribute to our inability
to address the opioid epidemic with what appears to be
a safe and efﬁcacious tool.
In light of the evidence presented in this article, and despite a lack of FDA approval, some U.S. states and private
treatment centers have already begun to include cannabis
as a part of OUD treatment protocols. The state of New
Jersey recently added OUD to their list of qualifying conditions for participation in the state’s medical cannabis
program.167,168 Some private treatment centers are also
citing the beneﬁts of harm reduction, which greatly outweigh the risks of cannabis use during the ﬁrst 28 days of
recovery, a critical time period for patient survival.76
Many clinicians remain skeptical of cannabis as a viable treatment option, either due to the stigma surrounding cannabis use or the belief that there is not enough
clinical evidence for them to feel conﬁdent providing
patients with cannabis recommendations.169 This is
unsurprising, given that 85% of recent medical school
graduates still receive no education whatsoever about
cannabis throughout their training, residencies, or fellowships.170 As the evidence in this ﬁeld accumulates,
it will be critically important to widen opportunities
for clinicians to participate in Continuing Medical Education programs, which include the harm reduction and
medical beneﬁts that cannabis could provide. Evidencebased opioid prescription and cannabis recommendation practices are a critical component of continuing
education, so that clinicians can continue to uphold
their Hippocratic oaths to ‘‘do no harm.’’
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25. Braida D, Iosuè S, Pegorini S, et al. D9-Tetrahydrocannabinol-induced
conditioned place preference and intracerebroventricular selfadministration in rats. Eur J Pharmacol. 2004;506:63–69.
26. Singh ME, Verty AN, McGregor IS, et al. A cannabinoid receptor antagonist attenuates conditioned place preference but not behavioural
sensitization to morphine. Brain Res. 2004;1026:244–253.
27. Wills KL, Parker LA. Effect of pharmacological modulation of the endocannabinoid system on opiate withdrawal: a review of the preclinical
animal literature. Front Pharmacol. 2016;7:187.
28. Yamaguchi T, Hagiwara Y, Tanaka H, et al. Endogenous cannabinoid, 2arachidonoylglycerol, attenuates naloxone-precipitated withdrawal
signs in morphine-dependent mice. Brain Res. 2001;909:121–126.
29. Sagheddu C, Muntoni AL, Pistis M, et al. Endocannabinoid signaling in
motivation, reward, and addiction: inﬂuences on mesocorticolimbic
dopamine function. Int Rev Neurobiol. 2015;125:257–302.
30. Befort K. Interactions of the opioid and cannabinoid systems in reward:
insights from knockout studies. Front Pharmacol. 2015;6:6.
31. Martin M, Ledent C, Parmentier M, et al. Cocaine, but not morphine,
induces conditioned place preference and sensitization to locomotor
responses in CB1 knockout mice. Eur J Neurosci. 2000;12:4038–4046.
32. Rice OV, Gordon N, Gifford AN. Conditioned place preference to morphine
in cannabinoid CB1 receptor knockout mice. Brain Res. 2002;945:135–138.
33. Lichtman AH, Sheikh SM, Loh HH, et al. Opioid and cannabinoid modulation of precipitated withdrawal in D9-tetrahydrocannabinol and
morphine-dependent mice. J Pharmacol Exp Ther. 2001;298:1007–1014.
34. Valverde O, Noble F, Beslot F, et al. D9-tetrahydrocannabinol releases
and facilitates the effects of endogenous enkephalins: reduction in
morphine withdrawal syndrome without change in rewarding effect.
Eur J Neurosci. 2001;13:1816–1824.
35. Massaly N, Morón JA, Al-Hasani R. A trigger for opioid misuse: chronic
pain and stress dysregulate the mesolimbic pathway and kappa opioid
system. Front Neurosci. 2016;10:480.
36. National Academies of Sciences, Engineering, and Medicine. The health
effects of cannabis and cannabinoids: the current state of evidence
and recommendations for research. National Academies Press: Washington, DC, 2017.
37. Boehnke KF, Litinas E, Clauw DJ. Medical cannabis use is associated
with decreased opiate medication use in a retrospective cross-sectional
survey of patients with chronic pain. J Pain. 2016;17:739–744.
38. Gruber SA, Sagar KA, Dahlgren MK, et al. Splendor in the grass? A pilot
study assessing the impact of medical marijuana on executive function.
Front Pharmacol. 2016;7:355.
39. Haroutounian S, Ratz Y, Ginosar Y, et al. The effect of medicinal cannabis
on pain and quality-of-life outcomes in chronic pain: a prospective
open-label study. Clin J Pain. 2016;32:1036–1043.
40. Kral AH, Wenger L, Novak SP, et al. Is cannabis use associated with less
opioid use among people who inject drugs? Drug Alcohol Depend.
2015;153:236–241.
41. Reiman A, Welty M, Solomon P. Cannabis as a substitute for opioidbased pain medication: patient self-report. Cannabis Cannabinoid Res.
2017;2:160–166.
42. Bellnier T, Brown GW, Ortega TR. Preliminary evaluation of the efﬁcacy,
safety, and costs associated with the treatment of chronic pain with
medical cannabis. Ment Health Clin. 2018;8:110–115.

Wiese and Wilson-Poe; Cannabis and Cannabinoid Research 2018, 3.1
http://online.liebertpub.com/doi/10.1089/can.2018.0022

43. Stith SS, Vigil JM, Adams IM, et al. Effects of legal access to cannabis on
scheduled II-V drug prescriptions. J Am Med Dir Assoc. 2018;19:59–64.e1.
44. Cichewicz DL, McCarthy EA. Antinociceptive synergy between D9tetrahydrocannabinol and opioids after oral administration. J Pharmacol
Exp Ther. 2003;304:1010–1015.
45. Kazantzis NP, Casey SL, Seow PW, et al. Opioid and cannabinoid synergy
in a mouse neuropathic pain model. Br J Pharmacol. 2016;173:2521–2531.
46. Phillips TJ, Cherry CL, Cox S, et al. Pharmacological treatment of painful
HIV-associated sensory neuropathy: a systematic review and metaanalysis of randomised controlled trials. PLoS One. 2010;5:e14433.
47. Roberts JD, Gennings C, Shih M. Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine. Eur J Pharmacol. 2006;530:54–58.
48. Abrams DI, Couey P, Shade SB, et al. Cannabinoid-opioid interaction in
chronic pain. Clin Pharmacol Ther. 2011;90:844–851.
49. Wilson AR, Maher L, Morgan MM. Repeated cannabinoid injections into
the rat periaqueductal gray enhance subsequent morphine antinociception. Neuropharmacology. 2008;55:1219–1225.
50. Smith PA, Selley DE, Sim-Selley LJ, et al. Low dose combination of
morphine and delta9-tetrahydrocannabinol circumvents antinociceptive tolerance and apparent desensitization of receptors. Eur J Pharmacol. 2007;571:129–137.
51. Lucas P, Walsh Z. Medical cannabis access, use, and substitution for
prescription opioids and other substances: a survey of authorized
medical cannabis patients. Int J Drug Policy. 2017;42:30–35.
52. Reiman A. Cannabis as a substitute for alcohol and other drugs. Harm
Reduc J. 2009;6:35.
53. Finn DP, Jhaveri MD, Beckett SR, et al. Effects of direct periaqueductal
grey administration of a cannabinoid receptor agonist on nociceptive
and aversive responses in rats. Neuropharmacology. 2003;45:594–604.
54. Jensen TS, Yaksh TL. Comparison of antinociceptive action of morphine
in the periaqueductal gray, medial and paramedial medulla in rat. Brain
Res. 1986;363:99–113.
55. Varvel SA, Bridgen DT, Tao Q, et al. Delta9-tetrahydrocannbinol accounts
for the antinociceptive, hypothermic, and cataleptic effects of marijuana
in mice. J Pharmacol Exp Ther. 2005;314:329–337.
56. Cooper ZD, Bedi G, Ramesh D, et al. Impact of co-administration of
oxycodone and smoked cannabis on analgesia and abuse liability.
Neuropsychopharmacology. 2018. [Epub ahead of print]; DOI: 10.1038/
s41386-018-0011-2.
57. Li JX, McMahon LR, Gerak LR, et al. Interactions between delta (9)tetrahydrocannabinol and mu opioid receptor agonists in rhesus monkeys: discrimination and antinociception. Psychopharmacology (Berl).
2008;199:199–208.
58. Christie MJ, Connor M, Vaughan CW, et al. Cellular actions of opioids and
other analgesics: implications for synergism in pain relief. Clin Exp
Pharmacol Physiol. 2000;27:520–523.
59. Fields HL, Heinricher MM. Anatomy and physiology of a nociceptive
modulatory system. Philos Trans R Soc Lond B Biol Sci. 1985;308:361–374.
60. Fyfe LW, Cleary DR, Macey TA, et al. Tolerance to the antinociceptive
effect of morphine in the absence of short-term presynaptic desensitization in rat periaqueductal gray neurons. J Pharmacol Exp Ther. 2010;
335:674–680.
61. Heinricher MM, Ingram SL. The Brainstem and Nociceptive Modulation.
In: Bushnell MC, Basbaum AI, eds. The Senses: A Comprehensive
Reference 5.41. Academic Press: Cambridge MA, 2008, pp. 593–626.
62. Wilson-Poe AR, Mitchell VA, Vaughan CW. Postsynaptic mGluR mediated
excitation of neurons in midbrain periaqueductal grey. Neuropharmacology. 2013;66:348–354.
63. Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM)
national practice guideline for the use of medications in the treatment
of addiction involving opioid use. J Addict Med. 2015;9:358–367.
64. Rehni AK, Jaggi AS, Singh N. Opioid withdrawal syndrome: emerging
concepts and novel therapeutic targets. CNS Neurol Disord Drug Targets. 2013;12:112–125.
65. Calabria B, Degenhardt L, Briegleb C, et al. Systematic review of prospective studies investigating ‘‘remission’’ from amphetamine, cannabis,
cocaine or opioid dependence. Addict Behav. 2010;35:741–749.
66. Ramsey SE, Rounsaville D, Hoskinson R, et al. The need for psychosocial
interventions to facilitate the transition to extended-release naltrexone
(XR-NTX) treatment for opioid dependence: a concise review of the literature. Subst Abuse. 2016;10:65–68.

187

67. Bart G. Maintenance medication for opiate addiction: the foundation of
recovery. J Addict Dis. 2012;31:207–225.
68. Center for Substance Abuse Treatment. Medication-assisted treatment
for opioid addiction in opioid treatment programs. Substance Abuse
and Mental Health Services Administration: Rockville, MD, 2005.
69. Connery HS. Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harv Rev Psychiatry. 2015;23:
63–75.
70. Fullerton CA, Kim M, Thomas CP, et al. Medication-assisted treatment with
methadone: assessing the evidence. Psychiatr Serv. 2014;65:146–157.
71. Gorodetzky CW, Walsh SL, Martin PR, et al. A phase III, randomized,
multi-center, double blind, placebo controlled study of safety and
efﬁcacy of lofexidine for relief of symptoms in individuals undergoing
inpatient opioid withdrawal. Drug Alcohol Depend. 2017;176:
79–88.
72. Schuckit MA. Treatment of opioid-use disorders. N Engl J Med. 2016;375:
357–368.
73. Novick DM, Salsitz EA, Joseph H, et al. Methadone medical maintenance:
an early 21st-century perspective. J Addict Dis. 2015;34:226–237.
74. Connock M, Juarez-Garcia A, Jowett S, et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review
and economic evaluation. Health Technol Assess. 2007;11:1–171, iii–iv.
75. Kreek MJ. Medical safety and side effects of methadone in tolerant individuals. JAMA. 1973;223:665–668.
76. Reed K, Day E, Keen J, et al. Pharmacological treatments for drug misuse
and dependence. Expert Opin Pharmacother. 2015;16:325–333.
77. Kimber J, Larney S, Hickman M, et al. Mortality risk of opioid substitution
therapy with methadone versus buprenorphine: a retrospective
cohort study. Lancet Psychiatry. 2015;2:901–908.
78. Kosten TR, O’Connor PG. Management of drug and alcohol withdrawal.
N Engl J Med. 2003;348:1786–1795.
79. Services USDOHaH. Substance Abuse and Mental Health Services
Administration Detoxiﬁcation and substance abuse treatment. 2017,
p. 49. Available at: https://store.samhsa.gov/shin/content/SMA15-4131/
SMA15-4131.pdf (accessed March 18, 2018).
80. Stein BD, Pacula RL, Gordon AJ, et al. Where is buprenorphine dispensed
to treat opioid use disorders? The role of private ofﬁces, opioid treatment programs, and substance abuse treatment facilities in urban and
rural counties. Milbank Q. 2015;93:561–583.
81. Fisher GL, Roget NA. Encyclopedia of substance abuse prevention,
treatment, and recovery. Sage: Thousand Oaks, CA, 2009.
82. Rosen K, Gutierrez A, Haller D, et al. Sublingual buprenorphine for
chronic pain: a survey of clinician prescribing practices. Clin J Pain. 2014;
30:295–300.
83. Jones JD, Manubay JM, Mogali S, et al. Abuse liability of intravenous
buprenorphine vs. buprenorphine/naloxone: importance of absolute
naloxone amount. Drug Alcohol Depend. 2017;179:362–369.
84. Alho H, Sinclair D, Vuori E, et al. Abuse liability of buprenorphine–
naloxone tablets in untreated IV drug users. Drug Alcohol Depend. 2007;
88:75–78.
85. Wesson DR, Ling W. The clinical opiate withdrawal scale (COWS). J
Psychoact Drugs. 2003;35:253–259.
86. Urnoski E. Why is buprenorphine coformulated with naloxone? JAAPA.
2017;30:44–45.
87. Wiegand TJ, Le Lait MC, Bartelson BB, et al. Analysis of the abuse and
diversion of the buprenorphine transdermal delivery system. J Pain.
2016;17:745–752.
88. Rosenblatt RA, Andrilla CHA, Catlin M, et al. Geographic and specialty
distribution of US physicians trained to treat opioid use disorder. Ann
Fam Med. 2015;13:23–26.
89. Sansone RA, Sansone LA. Buprenorphine treatment for narcotic addiction: not without risks. Innov Clin Neurosci. 2015;12:32–36.
90. Dick AW, Pacula RL, Gordon AJ, et al. Growth in buprenorphine waivers
for physicians increased potential access to opioid agonist treatment,
2002–11. Health Aff (Millwood). 2015;34:1028–1034.
91. Hutchinson E, Catlin M, Andrilla CHA, et al. Barriers to primary care
physicians prescribing buprenorphine. Ann Fam Med. 2014;12:
128–133.
92. Kakko J, Svanborg KD, Kreek MJ, et al. 1-year retention and social
function after buprenorphine-assisted relapse prevention treatment for
heroin dependence in Sweden: a randomised, placebo-controlled trial.
Lancet. 2003;361:662–668.

Wiese and Wilson-Poe; Cannabis and Cannabinoid Research 2018, 3.1
http://online.liebertpub.com/doi/10.1089/can.2018.0022

93. Hser YI, Saxon AJ, Huang D, et al. Treatment retention among patients
randomized to buprenorphine/naloxone compared to methadone in
a multi-site trial. Addiction. 2014;109:79–87.
94. Copenhaver MM, Bruce RD, Altice FL. Behavioral counseling content for
optimizing the use of buprenorphine for treatment of opioid dependence in community-based settings: a review of the empirical evidence.
Am J Drug Alcohol Abuse. 2007;33:643–654.
95. Montoya ID, Schroeder JR, Preston KL, et al. Inﬂuence of psychotherapy
attendance on buprenorphine treatment outcome. J Subst Abuse
Treat. 2005;28:247–254.
96. FDA Requirement. Post market drug safety information for patients and
providers. Available at: www.fda.gov/downloads/drugs/drugsafety/post
marketdrugsafetyinformationforpatientsandpro (accessed January 10, 2017).
97. BupPractice. Physician requirements to prescribe buprenorphine. Clinical Tools, Inc. 2014; Available at: https://www.buppractice.com/node/
4335 (accessed May 3, 2018).
98. Gowing L, Ali R, White JM. Opioid antagonists with minimal sedation
for opioid withdrawal. Cochrane Database Syst Rev. 2017;5:
CD002021.
99. Guo S, Manning V, Yang Y, et al. Lofexidine versus diazepam for the
treatment of opioid withdrawal syndrome: a double-blind randomized
clinical trial in Singapore. J Subst Abuse Treat. 2018;91:1–11.
100. Law FD, Diaper AM, Melichar JK, et al. Buprenorphine/naloxone versus
methadone and lofexidine in community stabilisation and detoxiﬁcation: a randomised controlled trial of low dose short-term opiatedependent individuals. J Psychopharmacol. 2017;31:1046–1055.
101. Deikel SM, Carder B. Attentuation of precipitated abstinence in
methadone-dependent rats by delta9-THC. Psychopharmacol Commun.
1976;2:61–65.
102. Fattore L, Deiana S, Spano SM, et al. Endocannabinoid system and opioid addiction: behavioural aspects. Pharmacol Biochem Behav. 2005;81:
343–359.
103. Hine B, Torrelio M, Gershon S. Attenuation of precipitated abstinence in
methadone-dependent rats by delta 9-THC. Psychopharmacol Commun. 1975;1:275–283.
104. Epstein DH, Preston KL. No evidence for reduction of opioid-withdrawal
symptoms by cannabis smoking during a methadone dose taper.
Am J Addict. 2015;24:323–328.
105. Navarro M, Carrera MR, Fratta W, et al. Functional interaction between
opioid and cannabinoid receptors in drug self-administration.
J Neurosci. 2001;21:5344–5350.
106. de Carvalho CR, Takahashi RN. Cannabidiol disrupts the reconsolidation
of contextual drug-associated memories in Wistar rats. Addict Biol.
2017;22:742–751.
107. Izzo AA, Borrelli F, Capasso R, et al. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends
Pharmacol Sci. 2009;30:515–527.
108. Thomas A, Baillie GL, Phillips AM, et al. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists
in vitro. Br J Pharmacol. 2007;150:613–623.
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Abbreviations Used
BNST ¼ bed nucleus of stria terminalis
CB1 ¼ cannabinoid 1
CBD ¼ cannabidiol
CeA ¼ central amygdala
CPA ¼ Conditioned Place Aversion
CPP ¼ conditioned place preference
CUD ¼ cannabis use disorder
DSM ¼ Diagnostic and Statistical Manual of Mental Disorders
FARS ¼ Fatality Analysis Reporting System
KO ¼ knockout
KOR ¼ kappa opioid receptor
MOR ¼ mu opioid receptor
NIDA ¼ National Institute of Drug Abuse
OUD ¼ opioid use disorder
PFC ¼ prefrontal cortex
POAs ¼ prescription opioid analgesics
THC ¼ tetrahydrocannabinol
VTA ¼ ventral tegmental area
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